Recommendations for the prevention of secondary Haemophilus influenzae type b (Hib) disease

Journal of Infection

Volumn 58, Issue 1, 2009, Pages 3-14

  Ladhani, Shamez ^a   Neely, Fiona ^b   Heath, Paul T ^c   Nazareth, Bernadette ^d   Roberts, Richard ^e   Slack, Mary P E ^a   McVernon, Jodie ^f   Ramsay, Mary E ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b Hampshire and Isle of Wight Health Protection Unit   (United Kingdom)

^c Vaccine Institute   (United Kingdom)

^d Norfolk Suffolk and Cambridgeshire Health Protection Unit   (United Kingdom)

^e PUBLIC HEALTH WALES   (United Kingdom)

^f MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

Author keywords

Contacts; Haemophilus influenzae; Hib; Prevention; Rifampicin

Indexed keywords

AMPICILLIN; AZITHROMYCIN; BACTERIUM ANTIBODY; CEFACLOR; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; CHLORAMPHENICOL; CLARITHROMYCIN; COTRIMOXAZOLE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN; MACROLIDE; MENITORIX; MOXIFLOXACIN; NAFCILLIN; PEDIACEL; RIFAMPICIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; ASPLENIA; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL MENINGITIS; CHEMOPROPHYLAXIS; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTACT EXAMINATION; DISEASE SEVERITY; EPIDEMIOLOGICAL DATA; EPIGLOTTITIS; ERADICATION THERAPY; FAMILY COUNSELING; HAEMOPHILUS INFLUENZAE TYPE B; HEALTH CARE PERSONNEL; HIGH RISK PATIENT; HOUSEHOLD; HUMAN; IMMUNE DEFICIENCY; IMMUNIZATION; INCIDENCE; INFECTION CONTROL; INFECTION SENSITIVITY; MEDICAL ASSESSMENT; MEDICAL LITERATURE; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT INDICATION; UNITED KINGDOM;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CARRIER STATE; CHILD; CHILD, PRESCHOOL; COMMUNICABLE DISEASE CONTROL; FAMILY HEALTH; GREAT BRITAIN; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HUMANS; INFANT; INFANT, NEWBORN;

EID: 59249106222     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2008.10.007     Document Type: Article

References (100)

1. Haemophilus influenzae type b (Hib). In: Salisbury D.M., Ramsay M.E., and Noakes K. (Eds). Immunisation against infectious disease. 3rd ed. (2006), The Stationary Office, London 127-142
2. Booy R. Getting Hib vaccine to those who need it. Lancet 351 (1998) 1446-1447
3. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 13 (2000) 302-317
4. Ramsay M.E., McVernon J., Andrews N.J., Heath P.T., and Slack M.P. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 188 (2003) 481-485
5. Heath P.T., Booy R., Azzopardi H.J., Slack M.P., Bowen-Morris J., Griffiths H., et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA 284 (2000) 2334-2340
6. Heath P.T., and McVernon J. The UK Hib vaccine experience. Arch Dis Child 86 (2002) 396-399
7. Fogarty J., Moloney A.C., and Newell J.B. The epidemiology of Haemophilus influenzae type b disease in the Republic of Ireland. Epidemiol Infect 114 (1995) 451-463
8. Herceg A. The decline of Haemophilus influenzae type b disease in Australia. Commun Dis Intell 21 (1997) 173-176
9. Garpenholt O., Silfverdal S.A., Hugosson S., Fredlund H., Bodin L., Romanus V., et al. The impact of Haemophilus influenzae type b vaccination in Sweden. Scand J Infect Dis 28 (1996) 165-169
10. Hargreaves R.M., Slack M.P., Howard A.J., Anderson E., and Ramsay M.E. Changing patterns of invasive Haemophilus influenzae disease in England and Wales after introduction of the Hib vaccination programme. BMJ 312 (1996) 160-161
11. Baker M., and Martin D. Hib disease rate plummets following immunisation programme. N Z Public Health Rep 2 (1995) 13-14
12. Cartwright K.A., Begg N.T., and Hull D. Chemoprophylaxis for secondary Haemophilus influenzae type b disease. CDR (Lond Engl Rev) 1 (1991) R2-R6
13. Cartwright K.A., Begg N.T., and Rudd P.T. Use of vaccines and antibiotic prophylaxis in contacts and cases of Haemophilus influenzae type b (Hib) disease. Commun Dis Rep CDR Rev 4 (1994) R16-R17
14. Anderson E.C., Begg N.T., Crawshaw S.C., Hargreaves R.M., Howard A.J., and Slack M.P. Epidemiology of invasive Haemophilus influenzae infections in England and Wales in the pre-vaccination era (1990-2). Epidemiol Infect 115 (1995) 89-100
15. Booy R., Hodgson S., Carpenter L., Mayon-White R.T., Slack M.P., Macfarlane J.A., et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 344 (1994) 362-366
16. Eskola J., Peltola H., Takala A.K., Kayhty H., Hakulinen M., Karanko V., et al. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. N Engl J Med 317 (1987) 717-722
17. Black S.B., Shinefield H.R., Fireman B., Hiatt R., Polen M., and Vittinghoff E. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J 10 (1991) 97-104
18. McVernon J., Trotter C.L., Slack M.P., and Ramsay M.E. Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. BMJ 329 (2004) 655-658
19. Sarangi J., Cartwright K., Stuart J., Brookes S., Morris R., and Slack M. Invasive Haemophilus influenzae disease in adults. Epidemiol Infect 124 (2000) 441-447
20. Ladhani S., Slack M.P., Heys M., White J., and Ramsay M.E. Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign. Arch Dis Child 93 (2008) 665-669
21. McVernon J., Andrews N., Slack M.P., and Ramsay M.E. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 361 (2003) 1521-1523
22. Greenberg D.P., Wong V.K., Partridge S., Chang S.J., Jing J., Howe B.J., et al. Immunogenicity of a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaccine. Pediatr Infect Dis J 19 (2000) 1135-1140
23. Heath P.T., and Ramsay M.E. Haemophilus influenzae type b vaccine-booster campaign. BMJ 326 (2003) 1158-1159
24. Gessner B.D., Sutanto A., Steinhoff M., Soewignjo S., Widjaya A., Nelson C., et al. A population-based survey of Haemophilus influenzae type b nasopharyngeal carriage prevalence in Lombok Island, Indonesia. Pediatr Infect Dis J 17 (1998) S179-S182
25. Gomez E., Moore A., Sanchez J., Kool J., Castellanos P.L., Feris J.M., et al. The epidemiology of Haemophilus influenzae type b carriage among infants and young children in Santo Domingo, Dominican Republic. Pediatr Infect Dis J 17 (1998) 782-786
26. Kuroki H., Ishikawa N., Uehara S., Himi K., Sonobe T., and Niimi H. Nasopharyngeal colonization with Haemophilus influenzae type b among infants and children in Japan. Acta Paediatr Jpn 39 (1997) 541-545
27. Olsen S.J., Dejsirilert S., Sangsuk L., Chunsutiwat S., and Dowell S.F. Frequent Haemophilus influenzae type B colonization in rural Thailand. Pediatr Infect Dis J 24 (2005) 739-742
28. Howard A.J., Dunkin K.T., and Millar G.W. Nasopharyngeal carriage and antibiotic resistance of Haemophilus influenzae in healthy children. Epidemiol Infect 100 (1988) 193-203
29. Daum R.S., Glode M.P., Goldmann D.A., Halsey N., Ambrosino D., Welborn C., et al. Rifampin chemoprophylaxis for household contacts of patients with invasive infections due to Haemophilus influenzae type b. J Pediatr 98 (1981) 485-491
30. Andersson von Rosen I., Gotherfors L., Schmeisser S., Tarnvik A., and Svanborg E.C. Outbreak of Haemophilus influenzae type b meningitis in a day care center. Pediatr Infect Dis J 9 (1990) 326-332
31. Murphy T.V., Granoff D., Chrane D.F., Olsen K.D., Barenkamp S.J., Dowell S.F., et al. Pharyngeal colonization with Haemophilus influenzae type b in children in a day care center without invasive disease. J Pediatr 106 (1985) 712-716
32. Gilbert G.L., MacInnes S.J., and Guise I.A. Rifampicin prophylaxis for throat carriage of Haemophilus influenzae type b in patients with invasive disease and their contacts. BMJ 302 (1991) 1432-1435
33. Cochi S.L., Fleming D.W., Hightower A.W., Limpakarnjanarat K., Facklam R.R., Smith J.D., et al. Primary invasive Haemophilus influenzae type b disease: a population-based assessment of risk factors. J Pediatr 108 (1986) 887-896
34. Li K.I., Dashefsky B., and Wald E.R. Haemophilus influenzae type b colonization in household contacts of infected and colonized children enrolled in day care. Pediatrics 78 (1986) 15-20
35. Glode M.P., Daum R.S., Boies E.G., Ballard T.L., Murray M., and Granoff D.M. Effect of rifampin chemoprophylaxis on carriage eradication and new acquisition of Haemophilus influenzae type b in contacts. Pediatrics 76 (1985) 537-542
36. Murphy T.V., Chrane D.F., McCracken Jr. G.H., and Nelson J.D. Rifampin prophylaxis v placebo for household contacts of children with Haemophilus influenzae type b disease. Am J Dis Child 137 (1983) 627-632
37. Band J.D., Fraser D.W., Hightower A.W., and Broome C.V. Prophylaxis of Haemophilus influenzae type b disease. JAMA 252 (1984) 3249-3250
38. Shapiro E.D., and Wald E.R. Efficacy of rifampin in eliminating pharyngeal carriage of Haemophilus influenzae type b. Pediatrics 66 (1980) 5-8
39. Barbour M.L., Booy R., Crook D.W., Griffiths H., Chapel H.M., Moxon E.R., et al. Haemophilus influenzae type b carriage and immunity four years after receiving the Haemophilus influenzae oligosaccharide-CRM197 (HbOC) conjugate vaccine. Pediatr Infect Dis J 12 (1993) 478-484
40. Takala A.K., Eskola J., Leinonen M., Kayhty H., Nissinen A., Pekkanen E., et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis 164 (1991) 982-986
41. Barbour M.L., Mayon-White R.T., Coles C., Crook D.W., and Moxon E.R. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis 171 (1995) 93-98
42. Castillo-Febres O., Lopez G., Ortegal F., Estopinan M., Casanova-Escalona L., Sanchez-Naveda M., et al. Oropharyngeal carriers in Venezuelan children in two child care settings, vaccinated or not with Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T). Invest Clin 46 (2005) 15-24
43. Adegbola R.A., Mulholland E.K., Secka O., Jaffar S., and Greenwood B.M. Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of Haemophilus influenzae type b among Gambian children. J Infect Dis 177 (1998) 1758-1761
44. McVernon J., Howard A.J., Slack M.P., and Ramsay M.E. Long-term impact of vaccination on Haemophilus influenzae type b (Hib) carriage in the United Kingdom. Epidemiol Infect 132 (2004) 765-767
45. Johnson N.G., Ruggeberg J.U., Balfour G.F., Lee Y.C., Liddy H., Irving D., et al. Haemophilus influenzae type b reemergence after combination immunization. Emerg Infect Dis 12 (2006) 937-941
46. Oh S.Y., Griffiths D., John T., Lee Y.C., Yu L.M., McCarthy N., et al. School-aged children: a reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom. J Infect Dis 197 (2008) 1275-1281
47. Brenneman G., Silimperi D., and Ward J. Recurrent invasive Haemophilus influenzae type b disease in Alaskan natives. Pediatr Infect Dis J 6 (1987) 388-392
48. Edmonson M.B., Granoff D.M., Barenkamp S.J., and Chesney P.J. Outer membrane protein subtypes and investigation of recurrent Haemophilus influenzae type b disease. J Pediatr 100 (1982) 202-208
49. Cates K.L., Krause P.J., Murphy T.V., Stutman H.R., and Granoff D.M. Second episodes of Haemophilus influenzae type b disease following rifampin prophylaxis of the index patients. Pediatr Infect Dis J 6 (1987) 512-515
50. Liston T.E. Pathogenesis and prevention of recurrent infection after Haemophilus influenzae bacteremia. Clin Pediatr (Phila) 23 (1984) 215-219
51. Band J.D., Fraser D.W., and Ajello G. Prevention of Haemophilus influenzae type b disease. JAMA 251 (1984) 2381-2386
52. Glode M.P., Daum R.S., Goldmann D.A., Leclair J., and Smith A. Haemophilus influenzae type B meningitis: a contagious disease of children. Br Med J 280 (1980) 899-901
53. Campbell L.R., Zedd A.J., and Michaels R.H. Household spread of infection due to Haemophilus influenzae type b. Pediatrics 66 (1980) 115-117
54. Granoff D.M., and Basden M. Haemophilus influenzae infections in Fresno County, California: a prospective study of the effects of age, race, and contact with a case on incidence of disease. J Infect Dis 141 (1980) 40-46
55. Ward J.I., Fraser D.W., Baraff L.J., and Plikaytis B.D. Haemophilus influenzae meningitis. A national study of secondary spread in household contacts. N Engl J Med 301 (1979) 122-126
56. Filice G.A., Andrews Jr. J.S., Hudgins M.P., and Fraser D.W. Spread of Haemophilus influenzae. Secondary illness in household contacts of patients with Haemophilus influenzae meningitis. Am J Dis Child 132 (1978) 757-759
57. Murphy T.V., Clements J.F., Breedlove J.A., Hansen E.J., and Seibert G.B. Risk of subsequent disease among day-care contacts of patients with systemic Haemophilus influenzae type B disease. N Engl J Med 316 (1987) 5-10
58. Osterholm M.T., Pierson L.M., White K.E., Libby T.A., Kuritsky J.N., and McCullough J.G. The risk of subsequent transmission of Haemophilus influenzae type B disease among children in day care. Results of a two-year statewide prospective surveillance and contact survey. N Engl J Med 316 (1987) 1-5
59. Fleming D.W., Leibenhaut M.H., Albanes D., Cochi S.L., Hightower A.W., Makintubee S., et al. Secondary Haemophilus influenzae type b in day-care facilities. Risk factors and prevention. JAMA 254 (1985) 509-514
60. Rijkers G.T., Vermeer-de Bondt P.E., Spanjaard L., Breukels M.A., and Sanders E.A. Return of Haemophilus influenzae type b infections. Lancet 361 (2003) 1563-1564
61. Spanjaard L., van den H.S., de Melker H.E., Vermeer-de Bondt P.E., van der E.A., and Rijkers G.T. Increase in the number of invasive Haemophilus influenzae type b infections. Ned Tijdschr Geneeskd 149 (2005) 2738-2742
62. Trotter C.L., McVernon J., Andrews N.J., Burrage M., and Ramsay M.E. Antibody to Haemophilus influenzae type b after routine and catch-up vaccination. Lancet 361 (2003) 1523-1524
63. Cox F., Trincher R., Rissing J.P., Patton M., McCracken Jr. G.H., and Granoff D.M. Rifampin prophylaxis for contacts of Haemophilus influenzae type b disease. JAMA 245 (1981) 1043-1045
64. Gessert C., Granoff D.M., and Gilsdorf J. Comparison of rifampin and ampicillin in day care center contacts of Haemophilus influenzae type b disease. Pediatrics 66 (1980) 1-4
65. Granoff D.M., Gilsdorf J., Gessert C., and Basden M. Haemophilus influenzae type B disease in a day care center: eradication of carrier state by rifampin. Pediatrics 63 (1979) 397-401
66. Li K.I., and Wald E.R. Use of rifampin in Haemophilus influenzae type b infections. Am J Dis Child 140 (1986) 381-385
67. Yogev R. The taxonomy and antimicrobial susceptibility of Haemophilus species in clinical specimens. Am J Clin Pathol 72 (1979) 133-134
68. Green M., Li K.I., Wald E.R., Guerra N., and Byers C. Duration of rifampin chemoprophylaxis for contacts of patients infected with Haemophilus influenzae type B. Antimicrob Agents Chemother 36 (1992) 545-547
69. Yogev R., Melick C., and Kabat K. Nasopharyngeal carriage of Haemophilus influenzae type b: attempted eradication by cefaclor or rifampin. Pediatrics 67 (1981) 430-433
70. Rowley A.H., Chadwick E.G., Kabat K., Sroka P., Shulman S.T., and Yogev R. Failure of a single dose of ceftriaxone to eradicate nasopharyngeal colonization of Haemophilus influenzae type b. J Pediatr 110 (1987) 792-794
71. Darouiche R., Perkins B., Musher D., Hamill R., and Tsai S. Levels of rifampin and ciprofloxacin in nasal secretions: correlation with MIC90 and eradication of nasopharyngeal carriage of bacteria. J Infect Dis 162 (1990) 1124-1127
72. Michaels R.H., and Norden C.W. Pharyngeal colonization with Haemophilus influenzae type b: a longitudinal study of families with a child with meningitis or epiglottitis due to Haemophilus influenzae type b. J Infect Dis 136 (1977) 222-228
73. Ogle J.W., Rabalais G.P., and Glode M.P. Duration of pharyngeal carriage of Haemophilus influenzae type b in children hospitalized with systemic infections. Pediatr Infect Dis 5 (1986) 509-511
74. Goldwater P.N. Effect of cefotaxime or ceftriaxone treatment on nasopharyngeal Haemophilus influenzae type b colonization in children. Antimicrob Agents Chemother 39 (1995) 2150-2152
75. Niederman M.S., Anzueto A., Sethi S., Choudhri S., Kureishi A., Haverstock D., et al. Eradication of Haemophilus influenzae in AECB: a pooled analysis of moxifloxacin phase III trials compared with macrolide agents. Respir Med 100 (2006) 1781-1790
76. Makintubee S., Istre G.R., and Ward J.I. Transmission of invasive Haemophilus influenzae type b disease in day care settings. J Pediatr 111 (1987) 180-186
77. Boies E.G., Granoff D.M., Squires J.E., and Barenkamp S.J. Development of Haemophilus influenzae type b meningitis in a household contact treated with rifampin. Pediatrics 70 (1982) 141-142
78. Murphy T.V., McCracken Jr. G.H., Moore B.S., Gulig P.A., and Hansen E.J. Haemophilus influenzae type b disease after rifampin prophylaxis in a day care center: possible reasons for its failure. Pediatr Infect Dis 2 (1983) 193-198
79. Wilde J., and Adler S.P. Molecular epidemiology of Haemophilus influenzae type B: failure of rifampin prophylaxis in a day care center. Pediatr Infect Dis 5 (1986) 505-508
80. Gilbert G.L. Epidemiology of Haemophilus influenzae type b disease in Australia and New Zealand. Vaccine 9 Suppl. (1991) S10-S13
81. Murphy T.V., McCracken Jr. G.H., Zweighaft T.C., and Hansen E.J. Emergence of rifampin-resistant Haemophilus influenzae after prophylaxis. J Pediatr 99 (1981) 406-409
82. McVernon J., Morgan P., Mallaghan C., Biswas T., Natarajan M., Griffiths D., et al. Outbreak of Haemophilus influenzae type b disease among fully vaccinated children in a day-care center. Pediatr Infect Dis J 23 (2004) 38-41
83. Granoff D.M., McKinney T., Boies E.G., Steele N.P., Oldfather J., Pandey J.P., et al. Haemophilus influenzae type b disease in an Amish population: studies of the effects of genetic factors, immunization, and rifampin prophylaxis on the course of an outbreak. Pediatrics 77 (1986) 289-295
84. Patterson J.E., Madden G.M., Krisiunas E.P., Masecar B., Hierholzer Jr. W.J., Zervos M.J., et al. A nosocomial outbreak of ampicillin-resistant Haemophilus influenzae type b in a geriatric unit. J Infect Dis 157 (1988) 1002-1007
85. O'Grady N.P., Alexander M., Dellinger E.P., Gerberding J.L., Heard S.O., Maki D.G., et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 51 (2002) 1-29
86. Weinbaum C., Lyerla R., and Margolis H.S. Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention. MMWR Recomm Rep 52 (2003) 1-36
87. Health Protection Agency Meningococcus Forum. Guidelines for public health management of meningococcal disease in the UK. Available at: (2006). [accessed October 2008]
88. Ladhani S., Heath P.T., Ramsay M.E., and Slack M.P. Changes in antibiotic resistance rates of invasive Haemophilus influenzae isolates in England and Wales over the last 20 years. J Antimicrob Chemother 62 (2008) 776-779
89. Grady R. Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J 22 (2003) 1128-1132
90. Alghasham A.A., and Nahata M.C. Clinical use of fluoroquinolones in children. Ann Pharmacother 34 (2000) 347-359
91. Committee on Infectious Diseases. The use of systemic fluoroquinolones. Pediatrics 118 (2006) 1287-1292
92. Anonymous. BNF for children 2007 (2007), BMJ Publishing Group Ltd.
93. Heath P.T., Booy R., Griffiths H., Clutterbuck E., Azzopardi H.J., Slack M.P., et al. Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood. Clin Infect Dis 31 (2000) 973-980
94. Ward J.I., Margolis H.S., Lum M.K., Fraser D.W., Bender T.R., and Anderson P. Haemophilus influenzae disease in Alaskan Eskimos: characteristics of a population with an unusual incidence of invasive disease. Lancet 1 (1981) 1281-1285
95. Levine O.S., Liu G., Garman R.L., Dowell S.F., Yu S., and Yang Y.H. Haemophilus influenzae type b and Streptococcus pneumoniae as causes of pneumonia among children in Beijing, China. Emerg Infect Dis 6 (2000) 165-170
96. Kristensen K. Carriage and antibiotic susceptibility of Haemophilus influenzae type b and non-b in Danish day-care attendees. APMIS 98 (1990) 50-52
97. Sung R.Y., Ling J.M., Fung S.M., Oppenheimer S.J., Crook D.W., Lau J.T., et al. Carriage of Haemophilus influenzae and Streptococcus pneumoniae in healthy Chinese and Vietnamese children in Hong Kong. Acta Paediatr 84 (1995) 1262-1267
98. Manary M.J., Lehmann D., Michael A., Coakley K., Taime J., Montgomery J., et al. Antigenuria in healthy Papua New Guinean children with nasal Haemophilus influenzae type b carriage. Ann Trop Paediatr 13 (1993) 385-389
99. Bakir M., Yagci A., Ulger N., Akbenlioglu C., Ilki A., Soyletir G., et al. Pharyngeal colonization with Haemophilus influenzae type b among healthy Turkish infants and children. Pediatr Int 44 (2002) 381-386
100. Ayyildiz A., Aktas A.E., and Yazgi H. Nasopharyngeal carriage rate of Haemophilus influenzae in children aged 7-12 years in Turkey. Int J Clin Pract 57 (2003) 686-688